Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

Abstract

AbstractBackgroundIn the development of anticancer agents for solid tumours, body surface area continues to be used to personalise dosing despite minimal evidence for its use over other dosing strategies. With the development of tyrosine kinase inhibitors and other oral targeted anticancer agents, dosing using therapeutic drug monitoring (TDM) is now utilised in many health systems but has had limited uptake in Australia.AimTo determine attitudes and barriers to the implementation of TDM among Australian oncologists.MethodsA comprehensive questionnaire was developed by the Dutch Pharmacology Oncology Group from semistructured interviews of stakeholders. Seventy‐nine questions across seven domains were developed with three free‐text responses. This was rationalised to 17 questions with three free‐text responses for Australian medical oncologists who identified limited experience with TDM.ResultsFifty‐seven responses were received, with 49 clinicians (86%) identifying limited experience of performing TDM in daily practice. Clinicians were positive (62–91% agree/strongly agree across seven questions) about the advantages of TDM. There was a mixed response for cost‐effectiveness and scientific evidence being a barrier to implementation, but strong agreement that prospective studies were needed (75% agreed or strongly agreed); that national treatment guidelines would enable practice (80%) and that a ‘pharmacology of oncolytics’ education programme would be useful (96%) to provide knowledge for dose individualisation.ConclusionDespite the limited experience of TDM in oncology in Australia, medical oncologists appear positive about the potential benefit to their patients. We have identified three barriers to implementation that could be targeted for increased adoption of TDM in oncology in Australia.